Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01103245 · ClinicalTrials.gov registry record · Phase 1
Aldosterone and the Metabolic Syndrome
A Phase 1 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT01103245 is a Phase 1 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 69 participants.
The verdict
NCT01103245, a Phase 1 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects of mineralocorticoid receptor (MR) antagonism and renin inhibition on glucose metabolism in humans.
Interventions
- DRUG Hydrochlorothiazide (HCTZ)
- DRUG Aliskiren 150 mg (ALI 150)
- DRUG Spironolactone (SPL 25)
- DRUG Aliskiren 300 mg (ALI 300)
- DRUG Spironolactone 50 mg (SPL 50)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2010-03 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01103245
The ClinicalTrials.gov registry entry for NCT01103245 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Hydrochlorothiazide (HCTZ) is the first listed.
NCT01103245 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01103245 about?
NCT01103245 is a clinical study titled "Aldosterone and the Metabolic Syndrome". The purpose of this study is to determine the effects of mineralocorticoid receptor (MR) antagonism and renin inhibition on glucose metabolism in humans.
What is the current status of trial NCT01103245?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2010-03. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01103245?
The interventions under investigation include: Hydrochlorothiazide (HCTZ) (DRUG), Aliskiren 150 mg (ALI 150) (DRUG), Spironolactone (SPL 25) (DRUG), Aliskiren 300 mg (ALI 300) (DRUG), Spironolactone 50 mg (SPL 50) (DRUG).
Who is sponsoring clinical trial NCT01103245?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.